EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Analysis of Factors Associated With Pathological Complete Response in Patients With HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy

Neda Stjepanovic, Sudhir Kumar, Katarzyna J Jerzak, Maureen Trudeau, Ellen Warner, Xingshan Cao, Andrea Eisen, William Tran, Rossanna C Pezo

Clinical Breast Cancer · 2024

DOI: 10.1016/j.clbc.2024.08.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2024. Verfasst von Neda Stjepanovic und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoadjuvant TherapyErb-b2 Receptor Tyrosine KinasesAntineoplastic Combined Chemotherapy ProtocolsTrastuzumabHumansFemaleMiddle AgedAdultAgedRetrospective StudiesDisease-Free SurvivalBiomarkers, TumorTaxoidsAnthracyclinesPrognosisIn Situ Hybridization, FluorescenceFollow-Up StudiesChemotherapy, Adjuvant

Stichwörter der Autor:innen

Early breast cancerHER2 expression levelNeoadjuvant settingPathological complete responseTrastuzumab

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabBiomarkers, TumorTaxoidsAnthracyclinesERBB2 protein, human

Autor:innen und Institutionen

  • Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada.
  • Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Research Design and Biostatistics, Sunnybrook Research Institute, Toronto, ON, Canada.
  • Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, ON, Canada; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada. Electronic address: rossanna.pezo@sunnybrook.ca.

Zitieren

APA

Stjepanovic, N., Kumar, S., Jerzak, K. J., Trudeau, M., Warner, E., Cao, X., Eisen, A., Tran, W., & Pezo, R. C. (2024). Analysis of Factors Associated With Pathological Complete Response in Patients With HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.08.010

Vancouver

Stjepanovic N, Kumar S, Jerzak KJ, Trudeau M, Warner E, Cao X, et al. Analysis of Factors Associated With Pathological Complete Response in Patients With HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy. Clinical Breast Cancer. 2024. doi:10.1016/j.clbc.2024.08.010

BibTeX
@article{Stjepanovic2024,
  author = {Stjepanovic, Neda and Kumar, Sudhir and Jerzak, Katarzyna J and Trudeau, Maureen and Warner, Ellen and Cao, Xingshan and Eisen, Andrea and Tran, William and Pezo, Rossanna C},
  title = {Analysis of Factors Associated With Pathological Complete Response in Patients With HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy},
  journal = {Clinical Breast Cancer},
  year = {2024},
  doi = {10.1016/j.clbc.2024.08.010}
}
Kostenlos starten →